Data show that anticoagulants will be very competitive in the coming years

According to a recent report released by Evaluate Pharma, the annual growth rate of anticoagulants is highest in the top 15 treatment areas, mainly due to Xarelto (rivaroxaban) and Boehringer, such as Bayer Corporation. New anticoagulant drugs such as Dabigatran etexilate (Pradaxa) from Ingelheim entered the market and were sufficient to fill the market decline caused by the expiration of patents by Sanofi-Aventis Enoxaparin (Lovenox).

At present, more than one anticoagulant drug is on the market at the same time, but whether these products can achieve commercial success remains to be seen. Currently, the overlord of the anticoagulant market is Lovenox. The drug is a low molecular weight heparin and the patent is about to expire. Although the drug's sales will not decline vertically, the industry agrees that the drug's sales in 2016 It will drop from 4.2 billion U.S. dollars in 2009 to 2.7 billion U.S. dollars.

Newly listed anticoagulants include Bayer's Factor Xa inhibitor Xarelto, which has been approved in Europe and received full response from the FDA early last year. It is expected that the drug will be re-applied at the end of this year. At the same time, Bristol-Myers Squibb also has a similar product Apixaban, which will also submit a new drug application to the FDA by the end of this year. In addition, DU-176b, the first pharmaceutical triad common factor Xa inhibitor, has entered phase III clinical trials in the world and has submitted a new drug application in Japan. Another drug for this market is Praderaxa, Boehringer Ingelheim's thrombin inhibitor, which has been approved in Europe.

The success of Lovenox shows that there is a huge demand for anticoagulants, and newer drugs must be improved in terms of safety or efficacy to prove why they are more valuable. In the next few years, the competition in the anticoagulant market will be fierce.

In other therapeutic areas, lipid-lowering drugs including statins will continue to maintain their status, even if Lipitor, the blockbuster drug in the field, loses patent protection. Another major category in the field of cardiovascular treatment is antihypertensive drugs, and will remain in its place, even if the entire class of angiotensin loses patent protection, the most prominent of which is Novartis's Diovan.

As for the vaccines that were neglected in previous years, they will continue to prove their value in terms of high sales and annual growth rates.